semaglutide evoke and evoke+: design of two large‐scale, double‐blind, placebo‐controlled, phase 3 studies evaluating the neuroprotective effects of in early Alzheimer's disease - Atri - 2022 - Alzheimer's & Dementia Data from the Evoke trials
Description
There was a recent radio show, 1A, discussing the benefits of ketamine for patients with treatment resistant depression
Glp-1 ile Glukagon Arasndaki liki Nedir?
Expanded uses in inflammatory bowel disease, neurological diseases, and metabolic dysfunction-associated steatohepatitis (MASH)
Primary outcomes included serious adverse events and retained gastric products based on patient records, procedure reports, and procedural videos
